Ho Jung Choi

Dr. Ho Jung Choi

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2022 in EBioMedicine
Verified
Journal Article
Open access
HCHo Jung Choi
Ho Jung Choi
IKInki Kim
Inki Kim
HLHye-Jin Lee
Hye-Jin Lee
HOHyun Ju Oh
Hyun Ju Oh
MAMi Kyoung Ahn
Mi Kyoung Ahn
KKKyung Mo Kim
Kyung Mo Kim
Few studies have described the aetiologies of neonatal cholestasis, and the overall neonatal cholestasis-related mortality (NCM) rate is unclear. We investigated the aetiology and outcome of neonatal cholestasis in a tertiary hospital and developed an NCM prediction model for these patients. Patients aged 1.0 mg/dL were retrospectively screened. Diagnostic and laboratory data during the 8-week follow-up period after enrolment between 2005 and 2020 were extracted digitally, and medical charts were reviewed manually by clinicians. Logistic regression was used to derive a prediction model for the 1-year mortality outcome of neonatal cholestasis, and performance evaluation and external validation were conducted for the NCM prediction model. We enrolled 4028 neonates with DB of >1.0 mg/dL at least once. Prematurity and birth injury (35.4%), complex heart anomalies (18.6%), liver diseases (11.4%), and gastrointestinal anomalies (9.2%) were the most common aetiologies; 398 (9.9%) patients died before one year of age. The peak value of DB was positively correlated to the 1-year mortality rate. In the multivariate analysis, simple laboratory indices, including platelet, prothrombin time, aspartate aminotransferase, albumin, direct bilirubin, creatinine, and C-reactive protein, were independent predictors of 1-year mortality outcome of complete-case subjects. Using these laboratory indices, a logistic regression-based NCM prediction model was constructed. It showed acceptable performances on discrimination (area under the curve, 0.916), calibration (slope, 1.04) and Brier scoring (0.072). The external validation of the sample (n = 920) from two other centres also revealed similar performance profiles of the NCM model. Various aetiologies of neonatal cholestasis were identified in a tertiary hospital, resulting in unfavourable outcomes of a large proportion. The NCM prediction model may have the potential to help clinicians to be aware of high-risk neonatal cholestasis.

21 March 2022 in World Journal of Gastroenterology
Verified
Journal Article
Open access
YKYeong Eun Kim
Yeong Eun Kim
HCHo Jung Choi
Ho Jung Choi
HLHye-Jin Lee
Hye-Jin Lee
HOHyun Ju Oh
Hyun Ju Oh
MAMi Kyoung Ahn
Mi Kyoung Ahn
KKKyung Mo Kim
Kyung Mo Kim
Assessment of pathogens and risk factors associated with bloodstream infection in the year after pediatric liver transplantation

1 January 2024 in Pediatrics International
Verified
Journal Article
Closed access
YKYeong Eun Kim
Yeong Eun Kim
SKSeo‐Hee Kim
Seo‐Hee Kim
SKSeong Pyo Kim
Seong Pyo Kim
YPYujin Park
Yujin Park
SKSu Hwan Kim
Su Hwan Kim
KKKyung Mo Kim
Kyung Mo Kim

1 January 2024 in Pediatric Gastroenterology, Hepatology & Nutrition
Verified
Journal Article
Open access
PDF file
YBYu Gyoung Bak
Yu Gyoung Bak
HCHo Jung Choi
Ho Jung Choi
YKYeong Eun Kim
Yeong Eun Kim
SOSeak Hee Oh
Seak Hee Oh
KKKyung Mo Kim
Kyung Mo Kim
Bak YG, et al. Pediatr Gastroenterol Hepatol Nutr. 2024 Jan;27(1):71-76. https://doi.org/10.5223/pghn.2024.27.1.71

1 January 2025 in Pediatrics International
Verified
Journal Article
Closed access
SCSeongjin Choi
Seongjin Choi
SKSeo‐Hee Kim
Seo‐Hee Kim
SKSeong Pyo Kim
Seong Pyo Kim
YPYujin Park
Yujin Park
SKSu Hwan Kim
Su Hwan Kim
KKKyung Mo Kim
Kyung Mo Kim

5 February 2026 in Antibiotics
Verified
Journal Article
Open access
PDF file
HCHo Jung Choi
Ho Jung Choi
YCYoon Kyung Cho
Yoon Kyung Cho
YKYe Ji Kim
Ye Ji Kim
Hyun Mi KangHyun Mi Kang
Hyun Mi Kang
DJDae Chul Jeong
Dae Chul Jeong
IYIn Hyuk Yoo
In Hyuk Yoo
Background/Objectives: Azithromycin is widely recommended as the first-line treatment for pediatric Campylobacter enterocolitis, although supporting evidence is limited and there is a lack of studies evaluating the efficacy of other macrolide antibiotics. This study aims to assess the effectiveness of starting macrolide therapy within three days of symptom onset in pediatric patients with Campylobacter enterocolitis. Methods: Pediatric patients under 19 years of age with a new diagnosis of Campylobacter enterocolitis were enrolled and randomly assigned to receive macrolide antibiotic treatment with either azithromycin or clarithromycin in a 1:1 ratio. Additionally, a retrospective historical cohort of pediatric patients diagnosed with Campylobacter enterocolitis prior to the study period, who did not receive macrolide antibiotics, was retrospectively reviewed for comparison. This dual approach allowed for the evaluation of macrolide therapy’s effectiveness against untreated cases. Results: The study included 27 patients in the macrolide group and 37 patients in the non-macrolide group. Baseline demographic and clinical characteristics were comparable between groups. Early macrolide therapy was associated with reduced hospital stay (3.8 ± 0.7 vs. 4.5 ± 0.9 days), shorter duration of diarrhea (1.8 ± 1.2 vs. 3.4 ± 0.7 days, p < 0.001), and shorter duration of fever (1.1 ± 0.6 vs. 2.8 ± 1.0 days, p < 0.001). No significant difference was observed in the duration of vomiting (p = 0.061). Conclusions: Early initiation of macrolide antibiotics in children with Campylobacter enterocolitis significantly accelerated complete clinical resolution and shortened hospitalization, particularly by hastening the resolution of diarrhea, fever, and abdominal pain. These findings support the use of early macrolide therapy for pediatric Campylobacter enterocolitis.